Todd Gray

• Project statistician for phase 3 trial in metastatic castrate resistant prostate cancer. • Wrote statistical analysis plans, analysis data set and output specifications • Involved in planning and implementation of futility analyses • Attend periodic DMC meetings and work with contractor providing output to DMC members • Provide statistical support for publications, abstracts, and professional meetings

- Provide statistical support to virology group in Global Biometric Sciences. Involved in the analysis and reporting of HBV and HCV clinical trial data - Provide statistical support for publications, abstracts, and professional meetings - Assist in the development of their phase 3 program in HCV

• Lead statistician for the phase 1 and 2 clinical trials of peginterferon-lambda in HCV • Lead statistician for the phase 2/3 clinical trial of atacicept in lupus nephritis • Lead statistician for the phase 3 clinical trial of spray rThrombin in surgical bleeding • Involved in the design, analysis, and reporting of phase 1-3 clinical trials • Wrote statistical analysis plans, analysis data set specifications, and output specifications • Provided statistical support for publications, abstracts, interna

• Lead statistician in Provenge® development project in prostate cancer • Wrote statistical analysis plans and programming specifications • Performed analyses of Provenge® phase 2/3 clinical trials • Contributed to the development of SOPs for the biometrics department • Provided statistical support to clinical manufacturing group for developing manufacturing specifications for Provenge® • Assisted vaccine development and QA departments in the analysis of bioassay data • Responsible for organizing and

• Global project statistician for Leukine® development project in Crohn’s disease • Study statistician for the phase 2 MS-275 study in metastatic melanoma • Represented biometrics at FDA meetings (end-of-phase 2, advisory meetings) • Involved in the design, analysis, and reporting of phase 2-3 clinical trials • Wrote statistical analysis plans and output specifications • Provided statistical support to other functional areas of the company (pharmacometrics, drug safety surveillance, discovery research,

• Global project statistician for Leukine® development project in Crohn’s disease • Study statistician for the phase 2 MS-275 study in metastatic melanoma • Represented biometrics at FDA meetings (end-of-phase 2, advisory meetings) • Involved in the design, analysis, and reporting of phase 2-3 clinical trials • Wrote statistical analysis plans and output specifications • Provided statistical support to other functional areas of the company (pharmacometrics, drug safety surveillance, discovery research,

• Lead statistician for phase 2 and 3 Visudyne® studies in age related macular degeneration, ocular histoplasmosis syndrome, and pathologic myopia • Involved in the design, analysis, and reporting of phase 2-3 clinical trials • Wrote statistical analysis plans and output specifications • Provided statistical support for manuscripts and publications • Interacted with data safety monitoring board for Visudyne® studies • Contributed to the development of departmental statistical SOP’s

- Lead statistician for phase 2 & 3 Visudyne® trials in AMD - Lead statistician for phase 2 study of Zaditor® in allergic conjunctivitis - Lead statistician for Visudyne® BLA - Wrote statistical analysis plans and output specifications - Attended FDA meetings (pre-NDA, end of phase II, advisory panel) - Provided statistical support for publications & manuscripts